言語を選択

GPRC5B

GPRC5B 製品リスト

属性
Protein (1)
製品ライブラリ
オンライン (1)
種
Human (1)
タグ
His Tag & Flag Tag (1)
マーカー
Unconjugated (1)

製品番号	種	発現システム	製品説明	タンパク質の構造	純度	特性
GPB-H52D7	Human	HEK293	Human GPRC5B Protein, Flag,His Tag (Detergent)

総数量1

GPRC5Bバックグランド

This gene encodes a member of the type 3 G protein-coupled receptor family. Members of this superfamily are characterized by a signature 7-transmembrane domain motif. The encoded protein may modulate insulin secretion and increased protein expression is associated with type 2 diabetes. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Feb 2015]

治験薬に関する情報

英語名	研究コード	研究開発ステージ	会社	適応症	臨床試験
Atacicept	TACI-Ig	Phase 3 Clinical	Zymogenetics Inc	Glomerulonephritis, IGA; Kidney Diseases; Arthritis, Rheumatoid; Multiple Sclerosis; Optic Neuritis; Lupus Nephritis; Urinary Bladder Diseases; Lupus Erythematosus, Systemic	詳細
Zigakibart	BION-1301	Phase 3 Clinical	Aduro Biotech Inc	Glomerulonephritis, IGA; Proteinuria; Multiple Myeloma	詳細
Povetacicept	ALPN-303; ALPN 30x	Phase 3 Clinical		Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Purpura, Thrombocytopenic, Idiopathic; Myasthenia Gravis; Glomerulonephritis, IGA; Sjogren's Syndrome; Glomerulonephritis, Membranous; Lupus Nephritis; Lupus Erythematosus, Systemic; Anemia, Hemolytic, Autoimmune; Inflammation; Cytopenia; Glomerulonephritis	詳細
Sibeprenlimab	VIS-649	Phase 3 Clinical	Visterra Inc	Glomerulonephritis, IGA; Glomerulonephritis	詳細
IM-21	IM21; IM-21	Phase 1 Clinical	Beijing Yimiao Medical Technology Co Ltd	Multiple Myeloma	詳細
Anti-BCMA CAR T-cell therapy (Actavis/Eugia Pharma)		Phase 1 Clinical	Eugia Pharma Specialities Ltd, Actavis Inc	Multiple Myeloma	詳細
anti-TriPRIL CAR T-cell therapy（Massachusetts General Hospital）		Phase 1 Clinical	Massachusetts General Hospital	Multiple Myeloma	詳細
AUR-200	AUR-200; AUR200	Phase 1 Clinical	Thunderbolt Pharma Inc	Autoimmune Diseases	詳細
RO-7297089	RO-7297089; AFM-26; RG-6296	Phase 1 Clinical	Genentech Inc	Multiple Myeloma	詳細
APRIL CAR-T Cell therapy (Yake Biotechnology)		Phase 1 Clinical	Shanghai YaKe Biotechnology Co Ltd	Multiple Myeloma	詳細
Anti-BCMA CAR T-cell therapy (Huazhong University of Science and Technology)		Clinical	Huazhong University Of Science And Technology	Multiple Myeloma	詳細

市販薬剤に関する情報

英語名	研究コード	研究開発ステージ	会社	オリジナル製品名	最初に承認をした国	最初の適応症	最初に承認を受けた会社	承認された日付	適応症	臨床試験
Telitacicept	RCT-18; RC-18; RCT18; RC18	Approved	RemeGen Co Ltd		Mainland China	Lupus Erythematosus, Systemic	RemeGen Co Ltd	2021-03-09	Myasthenia Gravis; Multiple Sclerosis, Relapsing-Remitting; Glomerulonephritis, IGA; Nephrosis; Immunoglobulin G4-Related Disease; Arthritis, Rheumatoid; Sjogren's Syndrome; Multiple Sclerosis; Lupus Nephritis; Neuromyelitis Optica; Lupus Erythematosus, Systemic	詳細